Research programme: AAV-based gene therapeutics - Tamid Bio

Drug Profile

Research programme: AAV-based gene therapeutics - Tamid Bio

Alternative Names: AAV gene therapy - Tamid Bio; Adenoviral-associated vector-mediated gene therapy - Tamid Bio; Tamid-001

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of North Carolina at Chapel Hill
  • Developer Tamid Bio; University of North Carolina at Chapel Hill
  • Class Gene therapies
  • Mechanism of Action Gene transference; Iduronidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Keratoplasty rejection; Mucopolysaccharidosis I; Muscular dystrophies

Most Recent Events

  • 05 Dec 2017 AAV-based gene therapeutics licensed to Tamid-Bio
  • 05 Dec 2017 Preclinical trials in Keratoplasty rejection in USA (unspecified route)
  • 05 Dec 2017 Preclinical trials in Mucopolysaccharidosis I in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top